Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Promyelocytic Leukemia With PML-RARA, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Conditions
Brief summary
This research study is looking at biomarkers in DNA samples from patients with acute lymphoblastic leukemia or acute myeloid leukemia. Studying samples of DNA from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Detailed description
PRIMARY OBJECTIVES: I. Collect DNA samples from patients with cytogenetically, well characterized, and uniformly treated acute lymphoblastic leukemia or acute myeloid leukemia for use in analysis of a wide range of host factors influencing etiology and outcome of the disease. II. Identify host factors that can be determined at onset of treatment to predict outcome of chemotherapy, and thus modify the therapy administered. OUTLINE: Previously collected DNA samples are analyzed for polymorphisms at a variety of loci. Gene expression and expression profiles are correlated with genotype and therapy outcomes.
Interventions
OTHERLaboratory Biomarker Analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* DNA samples available from patients meeting the following criteria: * Infants with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) * Patients with pre-B ALL, including responders vs non-responders in selected genotypes \[hyperdiploid, hypodiploid, t(12;21), t(9;22), t(1;19), and t(4;11)\] and responders and non-responders regardless of genotype * Pediatric patients with AML registered on POG-9421 * Adult patients with ALL, including t(8.21), inv(16), t(15;17), complex cytogenetics, and secondary AML * Pediatric patients with relapsed ALL enrolled on COG-AALL01P2 * Pediatric patients enrolled on COG-9900 and other CCG or POG trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differences in induction outcome, dichotomized into complete remission or no remission | Up to 8 years | Assessed with Fisher's exact test. |
| Differences in overall survival | Up to 8 years | Evaluated using the log rank statistic. |
| Disease-free survival (DFS) | Time from the end of induction to relapse or death, assessed up to 8 years | Evaluated using the log rank statistic. |
| Relapse-free survival | Time from the end of induction to marrow relapse or death from progressive disease, censoring on deaths from other causes, assessed up to 8 years | Evaluated using the logrank statistic. |
| Etiology of leukemia: Chi square test | Up to 8 years | Chi square test will be used to determine the differences in distribution of genotypes between cases and controls. |
| Etiology of leukemia: Fisher's exact test | Up to 8 years | Fisher's exact test will be used to determine the differences in distribution of genotypes between cases and controls. |
Countries
United States
Outcome results
None listed